Produção Nacional
O rituximabe como uma opção para pacientes com vasculite sistêmica grave refratária à terapia convencional: relato de sete casos e revisão de literatura
2015; Elsevier BV; Volume: 55; Issue: 6 Linguagem: Inglês
10.1016/j.rbr.2015.07.003
ISSN1809-4570
AutoresLeonardo Sales da Silva, Karla Valéria Miranda de Campos, Ana Karla Guedes de Melo, Alessandra Sousa Braz, Eutília Andrade Medeiros Freire,
Tópico(s)Otitis Media and Relapsing Polychondritis
ResumoThe greater understanding of pathophysiology and behavior of systemic vasculitis, together with the development of therapeutic regimens with increasingly better safety and efficacy profiles, dramatically changed the prognosis of patients diagnosed with these clinical entities. Recently, the use of rituximab in the treatment of patients with ANCA-associated vasculitis in randomized clinical trials showed an important alternative in selected cases, especially patients refractory or intolerant to standard therapy with cyclophosphamide and corticosteroids. This article presents the report of seven cases of systemic vasculitis successfully treated with rituximab.
Referência(s)